How I treat acquired clotting factor deficiency
10.3760/cma.j.cn121090-20250905-00414
- VernacularTitle:我如何治疗获得性凝血因子缺乏症
- Author:
Lei ZHANG
1
;
Wenjing GU
Author Information
1. 中国医学科学院血液病医院（中国医学科学院血液学研究所），血液与健康全国重点实验室，国家血液系统疾病临床医学研究中心，细胞生态海河实验室，天津 300020
- Publication Type:Journal Article
- From:
Chinese Journal of Hematology
2025;46(11):991-996
- CountryChina
- Language:Chinese
-
Abstract:
Acquired clotting factor deficiency encompasses bleeding disorders with diverse causes, including clotting factor inhibitors, liver disease, and disseminated intravascular coagulation. Among these, acquired clotting factor inhibitors are particularly rare and diagnostically challenging. Clinical management focuses on early recognition of bleeding, individualized therapy, and dynamic monitoring. In China, standardized protocols exist for acquired hemophilia A, while reports on other rare inhibitors are limited. Treatment strategies target both hemostasis and inhibitor eradication, with novel therapies for refractory cases. This article integrates clinical cases to provide practical guidance for standardized management.
